Quick Heal Technologies Ltd
QUICKHEALQuick Heal Technologies Ltd's price has outrun its earnings. −56.4% in a year against EPS −316.1% — the market is paying now for delivery later.
The sharpest disagreement: the price moved −56.4% in a year while annual EPS moved −316.1% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a downtrend (75 weeks in) while the P/E sits at the 100th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating, and 77% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Quick Heal Technologies Ltd trades at ₹163, in a downtrend and 75 weeks into that stage. That is −25.9% against its own 200-day average. It sits at 15% of a 52-week range of ₹133 to ₹336. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).
Today the stock is in a downtrend — week 75 of stage 4, confirmed. At ₹163 it trades −25.9% versus its 200-day average and sits at 15% of its 52-week range (₹133–₹336).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved −17% while the NIFTY 500 moved +280% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-06-25) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 100th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Quick Heal Technologies Ltd trades at 196.7× P/E, about the priciest it has ever traded. Its long-run median P/E is 21.1×, measured across 10.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 196.7× is about the priciest it has ever traded, against a long-run median of 21.1× measured over 10.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −316.1% against a −56.4% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the −12.0%/yr price move, ~−38.1%/yr came from earnings growth and ~+26.1 pp from the multiple (expanding); over 10y, of the −5.1%/yr price move, ~−18.9%/yr came from earnings growth and ~+13.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Quick Heal Technologies Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 10 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −6.8% | −2.1% | −4.8% | −1.4% |
| Share price | −56.4% | −0.7% | −12.0% | −5.1% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
27.9/100 — rank 51 of 63 in IT - Software · 65% evidence confidence
Quick Heal Technologies Ltd scores 27.9 out of 100 against the 63 companies it is compared with in IT - Software, ranking 51. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 7.5 + 6.8 + 10 + 3.6 = 27.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Quick Heal Technologies Ltd reported ₹49.0 Cr of revenue in the Mar 26 quarter, −24.6% year on year. Over 10 years it has compounded at −1.4% a year. The last full year, FY26, came in at ₹261 Cr. The last four reported quarters add to ₹262 Cr.
Quick Heal Technologies Ltd reported ₹49.0 Cr of revenue in the Mar 26 quarter, −24.6% year on year. Over 10 years it has compounded at −1.4% a year. The last full year, FY26, came in at ₹261 Cr. The last four reported quarters add to ₹262 Cr.
FY26 revenue came in at ₹261 Cr (−6.8% on the year), capping 10 years at −1.4% compound. The latest quarter (Mar 26) printed ₹49.0 Cr, −24.6% year on year.
Pace check: the last four quarters averaged −6.7% growth against the decade's −1.4% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −6.1% over the last 4 quarters against −5.1%/yr over the last 8 — stabilising.
→ Revenue slipped — did margins hold as it scaled? Next: −60.0% this quarter (−47.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Quick Heal Technologies Ltd's operating margin is −60.0% in the Mar 26 quarter, −47.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −11.0% to 42.0%. The current quarter is running below every full year in that window.
Quick Heal Technologies Ltd's operating margin is −60.0% in the Mar 26 quarter, −47.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −11.0% to 42.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is −60.0%, −47.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −11.0%–42.0%.
🚨 Why the margin moved: operating margin went −47.2 pp year on year while gross margin went +1.7 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins slipped — did that reach the bottom line? Next: profit null in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Quick Heal Technologies Ltd posted a net loss of ₹20.0 Cr in the Mar 26 quarter. The full FY26 year was a loss of ₹11.0 Cr. That loss is 40.8% of the quarter's revenue. The same quarter a year earlier lost ₹3.0 Cr. 4 of the last 12 reported quarters were loss-making.
Quick Heal Technologies Ltd posted a net loss of ₹20.0 Cr in the Mar 26 quarter. The full FY26 year was a loss of ₹11.0 Cr. That loss is 40.8% of the quarter's revenue. The same quarter a year earlier lost ₹3.0 Cr. 4 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹−20.0 Cr, null year on year. On the full year, FY26 printed ₹−11.0 Cr (−320.0%).
→ Profit rose — but did the cash follow? Next: 77% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 77% of Quick Heal Technologies Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹15.0 Cr of operating cash against ₹−11.0 Cr of profit. After ₹17.0 Cr of capital spending, ₹−2.0 Cr was left as free cash.
FY26: operating cash of ₹15.0 Cr against reported profit of ₹−11.0 Cr, leaving free cash of ₹−2.0 Cr after ₹17.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 77% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 77%: the cash cycle stretched 27 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: conversion is below par and the cash cycle has stretched 27 days — the next section's job is to find where the cash is stuck.
→ So follow the cash to where it goes. Next: the 192-day cycle, in money terms.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Quick Heal Technologies Ltd's cash conversion cycle runs 192 days in FY26, up from 165 days in FY21. Capital spending ran ₹38.0 Cr over the last 3 years. At FY26 sales of ₹261 Cr each day of that cycle holds about ₹0.7 Cr, so roughly ₹137 Cr sits inside the business at any moment.
FY26: debtors at 192 days (an asset-light business — no inventory to speak of) — for a full cycle of 192 days, looser than FY21's 165.
In money terms: at FY26 sales of ₹261 Cr, each day of the cycle holds about ₹0.7 Cr — so the 192-day loop keeps roughly ₹137 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹38.0 Cr over the last 3 fiscal years against ₹40.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
→ Does all this activity actually earn its cost of capital? Next: ROCE is −5% and the ROIC − WACC spread is −30.0 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Quick Heal Technologies Ltd earns a ROCE of −5% in FY26. Return on invested capital clears the cost of that capital by −30.0 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −4.2% net margin on 0.48× asset turns.
FY26 ROCE is −5%.
🚨 Why the return is what it is — the wiring (FY26): −4.2% net margin × 0.48× asset turns × 1.25× balance-sheet leverage ≈ −2.5% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: −18.0% − 12.0% = a −30.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.00.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Quick Heal Technologies Ltd carries ₹0.0 Cr of borrowings against ₹436 Cr of equity in FY26, a debt-to-equity of 0.00. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr. Capital spending ran ₹38.0 Cr across the last 3 of those years.
FY26: borrowings of ₹0.0 Cr against equity of ₹436 Cr — a debt-to-equity of 0.00. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr while capital spending ran ₹38.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions cut 2.4 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 2.4 points of Quick Heal Technologies Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 0.0% of the company. Foreign institutions moved −1.1 points over the same window, to 0.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −2.4 points over 8 quarters to 0.0%; Foreign institutions: −1.1 points over 8 quarters to 0.5%; Promoters: −1.0 points over 8 quarters to 71.5%.
🚨 Why the register moved: domestic institutions drove it (−2.4 points), alongside foreign institutions (−1.1 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Quick Heal Technologies Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Quick Heal Technologies Ltd this page | 196.7× | ₹829 Cr | No read | |||
| Tata Consultancy Services Ltd | 15.2× | ₹8.2L Cr | Consistent | |||
| Infosys Ltd | 13.6× | ₹4.2L Cr | Consistent | |||
| HCL Technologies Ltd | 19.0× | ₹3.4L Cr | Mixed | |||
| Wipro Ltd | 13.3× | ₹1.8L Cr | Topping out | |||
| Tech Mahindra Ltd | 28.7× | ₹1.5L Cr | Topping out | |||
| LTM Ltd | 21.6× | ₹1.2L Cr | Consistent | |||
| Coforge Ltd | 40.0× | ₹65,726 Cr | Mixed | |||
| Mphasis Ltd | 22.6× | ₹43,674 Cr | Consistent | |||
| Hexaware Technologies Ltd | 23.0× | ₹33,719 Cr | No read | |||
| IDream Film Infrastructure Company Ltd | — | ₹17,180 Cr | No read | |||
| Zensar Technologies Ltd | 15.1× | ₹11,511 Cr | Turning around | |||
| Sonata Software Ltd | 15.8× | ₹8,079 Cr | Mixed | |||
| Tanla Platforms Ltd | 14.9× | ₹7,954 Cr | Turning around | |||
| Birlasoft Ltd | 14.8× | ₹7,896 Cr | Turning around | |||
| Seshaasai Technologies Ltd | 23.6× | ₹6,221 Cr | No read | |||
| ASM Technologies Ltd | 103.0× | ₹6,206 Cr | No read | |||
| AvenuesAI Ltd | 20.2× | ₹5,700 Cr | Mixed | |||
| Mastek Ltd | 12.0× | ₹5,242 Cr | Consistent | |||
| Datamatics Global Services Ltd | 20.3× | ₹4,856 Cr | Topping out | |||
| Aurionpro Solutions Ltd | 21.0× | ₹4,562 Cr | Mixed | |||
| Moschip Technologies Ltd | 141.0× | ₹4,508 Cr | Mixed | |||
| Capillary Technologies India Ltd | 128.0× | ₹3,790 Cr | — | — | — | — |
| TechNVision Ventures Ltd | 984.0× | ₹3,563 Cr | No read | |||
| Cigniti Technologies Ltd | 11.4× | ₹3,472 Cr | Mixed | |||
| 63 Moons Technologies Ltd | — | ₹3,264 Cr | No read | |||
| ASM Technologies Ltd | 52.8× | ₹3,220 Cr | No read | |||
| TechNVision Ventures Ltd | 14,485.0× | ₹3,187 Cr | No read | |||
| R Systems International Ltd | 12.6× | ₹2,909 Cr | Turning around | |||
| Sasken Technologies Ltd | 48.1× | ₹2,765 Cr | Improving | |||
| BLS E-Services Ltd | 44.6× | ₹2,565 Cr | Mixed | |||
| Silver Touch Technologies Ltd | 71.0× | ₹2,538 Cr | Turning around | |||
| Saksoft Ltd | 16.3× | ₹2,231 Cr | Mixed | |||
| Blue Cloud Softech Solutions Ltd | 31.2× | ₹1,889 Cr | Mixed | |||
| Hypersoft Technologies Ltd | 440.0× | ₹1,798 Cr | No read | |||
| Kody Technolab Ltd | 104.0× | ₹1,748 Cr | — | — | — | — |
| IZMO Ltd | 34.8× | ₹1,653 Cr | Improving | |||
| NINtec Systems Ltd | 50.3× | ₹1,610 Cr | Mixed | |||
| Dynacons Systems & Solutions Ltd | 18.6× | ₹1,580 Cr | Mixed | |||
| Magellanic Cloud Ltd | 13.6× | ₹1,568 Cr | Mixed |
Frequently asked questions
What is Quick Heal Technologies Ltd's share price today?
Quick Heal Technologies Ltd trades at ₹163, −56.4% over the past year. The company is valued at ₹829 Cr. The stock sits at 15% of its 52-week range of ₹133–₹336, −25.9% versus its 200-day average. On the tape, the price is in a downtrend, 75 weeks in. — as of 24 July 2026.
What were Quick Heal Technologies Ltd's latest quarterly results?
Quick Heal Technologies Ltd reported revenue of ₹49.0 Cr and a net loss of ₹20.0 Cr for the Mar 26 quarter. Earnings per share were ₹−3.68. The operating margin was −60.0%, 47.0 pp lower than a year earlier. — as of 24 July 2026.
What is Quick Heal Technologies Ltd's revenue?
Quick Heal Technologies Ltd reported revenue of ₹49.0 Cr in the Mar 26 quarter, −24.6% year on year. For the full FY26 fiscal year, revenue was ₹261 Cr (−6.8%). Over the last 10 years revenue compounded at −1.4% a year. — as of 24 July 2026.
What is Quick Heal Technologies Ltd's profit?
Quick Heal Technologies Ltd earned ₹−20.0 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹−11.0 Cr. The operating margin ran −60.0% in the latest quarter. — as of 24 July 2026.
What is Quick Heal Technologies Ltd's market cap?
Quick Heal Technologies Ltd's market capitalisation is ₹829 Cr at a share price of ₹163. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Quick Heal Technologies Ltd's P/E ratio?
Quick Heal Technologies Ltd trades at a P/E of 196.7×, at the 100th percentile of its own 10-year range, against a long-run median of 21.1×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Quick Heal Technologies Ltd pay a dividend?
Not in its latest year — Quick Heal Technologies Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 11 of its last 13 reported fiscal years, so there is a history but no current dividend. — as of 24 July 2026.
Is Quick Heal Technologies Ltd overvalued?
On its own history, Quick Heal Technologies Ltd looks expensive against its own history: its P/E of 196.7× sits at the 100th percentile of its 10-year range (long-run median 21.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
How is Quick Heal Technologies Ltd performing?
Quick Heal Technologies Ltd is in a downtrend, 75 weeks in. Against the NIFTY 500 it has been behind on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
Is Quick Heal Technologies Ltd in an uptrend?
No — the price is in a downtrend (week 75 of stage 4), trading −25.9% versus its 200-day average and at 15% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Quick Heal Technologies Ltd beating the market?
Not lately — on a trailing-13-week view Quick Heal Technologies Ltd is currently behind the NIFTY 500 (4 weeks and counting; last ahead the week of 2026-06-25), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved −17% against the NIFTY 500's +280% — behind the index over the full window. — as of 24 July 2026.
Will Quick Heal Technologies Ltd's share price go up?
This page publishes no price forecast for Quick Heal Technologies Ltd. What it measures instead: the share price is ₹163, the price is in a downtrend 75 weeks in. Its P/E of 196.7× sits at the 100th percentile of its own 10-year range. — as of 24 July 2026.
Who owns Quick Heal Technologies Ltd?
Promoters hold 71.5% of Quick Heal Technologies Ltd, foreign institutions 0.5%, domestic institutions 0.0% and the public 28.1% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 2.4 points over 8 quarters. — as of 24 July 2026.
Does Quick Heal Technologies Ltd have too much debt?
No — Quick Heal Technologies Ltd's debt-to-equity is 0.00. FY26 borrowings were ₹0.0 Cr against equity of ₹436 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Quick Heal Technologies Ltd's capex?
Quick Heal Technologies Ltd spent ₹38.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹17.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Quick Heal Technologies Ltd's cash flow?
Quick Heal Technologies Ltd generated ₹15.0 Cr of operating cash flow in FY26 and ₹−2.0 Cr of free cash flow after ₹17.0 Cr of capital spending. Reported profit that year was ₹−11.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Quick Heal Technologies Ltd's profit real cash?
Mostly — over the last 3 fiscal years, 77% of Quick Heal Technologies Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹15.0 Cr against reported profit of ₹−11.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 24 July 2026.
Where is Quick Heal Technologies Ltd in its business cycle?
Quick Heal Technologies Ltd's FY26 operating margin was −11.0%, against a 13-year band of −11.0%–42.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran −60.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Quick Heal Technologies Ltd story?
The sharpest disagreement: the price moved −56.4% in a year while annual EPS moved −316.1% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Quick Heal Technologies Ltd a stock worth studying right now?
This is not investment advice. The machine read: Quick Heal Technologies Ltd's price has outrun its earnings. −56.4% in a year against EPS −316.1% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.